March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
After Multiple Rounds of Mass Drug Administration for Trachoma, are there only "Trachoma families" left?
Author Affiliations & Notes
  • Sheila K. West
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Beatriz E. Munoz
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Harran Mkocha
    Kongwa Trachoma Project, Kongwa, Tanzania, United Republic of
  • Charlotte Gaydos
    Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland
  • Thomas Quinn
    National Institute of Allergy and Infectious diseases, National Institute of Allergy and Infectious diseases, NIH,, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  Sheila K. West, None; Beatriz E. Munoz, None; Harran Mkocha, None; Charlotte Gaydos, None; Thomas Quinn, None
  • Footnotes
    Support  Research to Prevent Blindness, Bill and Melinda Gates Foundation
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6936. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sheila K. West, Beatriz E. Munoz, Harran Mkocha, Charlotte Gaydos, Thomas Quinn; After Multiple Rounds of Mass Drug Administration for Trachoma, are there only "Trachoma families" left?. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6936.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Mass drug administration (MDA) with azithromycin in areas with endemic trachoma is part of the World Health Organization (WHO) SAFE strategy, and at least 3 rounds of MDA are recommended. We hypothesized that after each successive round of MDA as infection declined, trachoma and infection would be increasingly clustered in a few high risk families in the communities, and the proportion of families with an isolated child with infection would decline.

Methods: : In four villages in Kongwa Tanzania, a longitudinal cohort of children ages under ten years at baseline was followed up to 30 months post 3 rounds of MDA. MDA was carried out at baseline, 12, and 24 months, with coverage with azithromycin over 90% in each round. Surveys for infection with C. trachomatis and clinical trachoma were carried out at baseline, 6, 12, 18, 24, and 30 months. A trained grader used the WHO simplified grading system determined the presence of active trachoma. Ocular swabs were collected and shipped to the International Chlamydia laboratory at JHU for determination of infection using Amplicor polymerase chain reaction. We studied the sub set of households with at least 2 children/ household in order to allow more than one child to be infected. We determined the percentage of households with infection after each round of MDA, and the percentage of children infected in each household.

Results: : At baseline, 2210 children under age ten years resided in 963 households. The overall prevalence of trachoma was 27% and infection was 22%. There were 261 households with at least one infection and who contained more than one child, and 50.6% of them had more than one child infected. By 30 months, infection declined to 3% and trachoma to 9%. There were only 53 households with more than one child and at least one infection, reflecting the overall decline in prevalence. Only 35.8% of them had more than one child infected.

Conclusions: : This prospective study did not find evidence of increased clustering of infections within a few households after multiple rounds of MDA. In fact, proportionately more households after 3 rounds of MDA had a single child infection than was the case at baseline. It appears that although infection declines with each successive round of MDA in these communities, the pattern of clustering does not change.

Keywords: trachoma • antibiotics/antifungals/antiparasitics • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×